Anyone starting or continuing a compounded GLP-1 program right now should understand the FDA's April 2026 proposal, ask their telehealth platform about pharmacy structure, and have a conversation with their clinician about contingency planning for their care if compounding availability changes
This framework generates testable predictions and potential monitoring endpointsincluding lean mass trajectory, micronutrient status, fat-soluble vitamin surveillance, and exploratory redox-related biomarkersthat can be evaluated in future longitudinal and interventional studies
The suggested formulations are provided for reference only and are based on formulations that have historically been ordered by duly licensed professionals
Annals Of Internal Medicine, 154
If sexual side effects are persistent and significantly impacting quality of life after exhausting other strategies, discussing a switch to a different medication class or a different GLP-1 agonist with your provider is reasonable